| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.4 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |